First‐in‐Human Studies of Pharmacokinetics and Safety of Utreloxastat (PTC857), a Novel 15‐Lipooxygenase Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis

Autor: Lan Gao, Peter Giannousis, Martin Thoolen, Diksha Kaushik, Joey Latham, Aaron Tansy, Jiyuan Ma, Mayzie Johnston, Mandar Dali, Lee Golden, Matthew Klein, Ronald Kong, Jeffrey Trimmer
Rok vydání: 2022
Předmět:
Zdroj: Clinical Pharmacology in Drug Development. 12:141-151
ISSN: 2160-7648
2160-763X
Popis: Utreloxastat (PTC857) is a 15-lipoxygenase inhibitor being developed to treat amyotrophic lateral sclerosis. This first-in-human study investigated the safety and pharmacokinetics of utreloxastat in healthy volunteers (N = 82) in a double-blind, placebo-controlled trial. The effects of a single ascending dose (100-1000 mg), multiple ascending doses (150-500 mg), and food (500 mg) on the pharmacokinetics and safety of utreloxastat were evaluated. Following single doses, the time to maximum plasma concentration (C
Databáze: OpenAIRE
Externí odkaz: